Does the media favor MIRM or MRNA?

In the previous week, Moderna had 62 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 82 mentions for Moderna and 20 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.27 beat Moderna's score of 0.43 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 38 Very Positive mention(s) 15 Positive mention(s) 8 Neutral mention(s) 9 Negative mention(s) 10 Very Negative mention(s) Neutral

Does the media favor MIRM or INCY?

In the previous week, Incyte had 19 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 39 mentions for Incyte and 20 mentions for Mirum Pharmaceuticals. Incyte's average media sentiment score of 1.39 beat Mirum Pharmaceuticals' score of 1.27 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 29 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer BNTX or MIRM?

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than BioNTech. MarketBeat recorded 20 mentions for Mirum Pharmaceuticals and 19 mentions for BioNTech. Mirum Pharmaceuticals' average media sentiment score of 1.27 beat BioNTech's score of -0.04 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral Mirum Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MIRM or UTHR?

In the previous week, United Therapeutics had 21 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 41 mentions for United Therapeutics and 20 mentions for Mirum Pharmaceuticals. United Therapeutics' average media sentiment score of 1.45 beat Mirum Pharmaceuticals' score of 1.27 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 32 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MIRM or GMAB?

In the previous week, Mirum Pharmaceuticals had 15 more articles in the media than Genmab A/S. MarketBeat recorded 20 mentions for Mirum Pharmaceuticals and 5 mentions for Genmab A/S. Mirum Pharmaceuticals' average media sentiment score of 1.27 beat Genmab A/S's score of 0.98 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mirum Pharmaceuticals (MIRM) Competitors

$97.46 -2.29 (-2.30%)

As of 08/28/2026 04:00 PM Eastern

Compare

MIRM vs. MRNA, INCY, BNTX, UTHR, and GMAB

Should you buy Mirum Pharmaceuticals stock or one of its competitors? Mirum Pharmaceuticals's main competitors and comparable companies include Moderna (MRNA), Incyte (INCY), BioNTech (BNTX), United Therapeutics (UTHR), and Genmab A/S (GMAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mirum Pharmaceuticals compare to Moderna?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Mirum Pharmaceuticals has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$618.07M	10.24	-$23.36M	-$14.55	N/A
Moderna	$2.21B	24.93	-$2.82B	-$7.99	N/A

Mirum Pharmaceuticals has a net margin of -139.18% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Moderna	-141.43%	-28.30%	-19.39%

Mirum Pharmaceuticals currently has a consensus target price of $137.31, suggesting a potential upside of 40.89%. Moderna has a consensus target price of $80.53, suggesting a potential downside of 41.64%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Mirum Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Moderna	3 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.17

75.3% of Moderna shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Mirum Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

In the previous week, Moderna had 62 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 82 mentions for Moderna and 20 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.27 beat Moderna's score of 0.43 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	38 Very Positive mention(s)	15 Positive mention(s)	8 Neutral mention(s)	9 Negative mention(s)	10 Very Negative mention(s)	Neutral

Summary

Mirum Pharmaceuticals beats Moderna on 9 of the 17 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Incyte?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Incyte has a net margin of 27.71% compared to Mirum Pharmaceuticals' net margin of -139.18%. Incyte's return on equity of 29.93% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Incyte	27.71%	29.93%	22.88%

Mirum Pharmaceuticals presently has a consensus price target of $137.31, suggesting a potential upside of 40.89%. Incyte has a consensus price target of $123.10, suggesting a potential downside of 1.02%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Mirum Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Incyte	0 Sell rating(s)	12 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.56

Incyte has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$618.07M	10.24	-$23.36M	-$14.55	N/A
Incyte	$5.82B	4.33	$1.29B	$7.85	15.84

97.0% of Incyte shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Mirum Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Incyte has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

In the previous week, Incyte had 19 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 39 mentions for Incyte and 20 mentions for Mirum Pharmaceuticals. Incyte's average media sentiment score of 1.39 beat Mirum Pharmaceuticals' score of 1.27 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	29 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Incyte beats Mirum Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

BioNTech has a net margin of -63.54% compared to Mirum Pharmaceuticals' net margin of -139.18%. BioNTech's return on equity of -6.86% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioNTech has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

Mirum Pharmaceuticals has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.65B	9.74	-$1.29B	-$7.83	N/A
Mirum Pharmaceuticals	$618.07M	10.24	-$23.36M	-$14.55	N/A

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than BioNTech. MarketBeat recorded 20 mentions for Mirum Pharmaceuticals and 19 mentions for BioNTech. Mirum Pharmaceuticals' average media sentiment score of 1.27 beat BioNTech's score of -0.04 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech presently has a consensus target price of $127.81, suggesting a potential upside of 25.22%. Mirum Pharmaceuticals has a consensus target price of $137.31, suggesting a potential upside of 40.89%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

BioNTech beats Mirum Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to United Therapeutics?

Mirum Pharmaceuticals (NASDAQ:MIRM) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Mirum Pharmaceuticals presently has a consensus price target of $137.31, indicating a potential upside of 40.89%. United Therapeutics has a consensus price target of $646.00, indicating a potential upside of 25.32%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Mirum Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, United Therapeutics had 21 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 41 mentions for United Therapeutics and 20 mentions for Mirum Pharmaceuticals. United Therapeutics' average media sentiment score of 1.45 beat Mirum Pharmaceuticals' score of 1.27 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	32 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

94.1% of United Therapeutics shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

United Therapeutics has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$618.07M	10.24	-$23.36M	-$14.55	N/A
United Therapeutics	$3.18B	6.95	$1.33B	$27.95	18.44

United Therapeutics has a net margin of 41.56% compared to Mirum Pharmaceuticals' net margin of -139.18%. United Therapeutics' return on equity of 20.18% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
United Therapeutics	41.56%	20.18%	17.98%

Summary

United Therapeutics beats Mirum Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Mirum Pharmaceuticals compare to Genmab A/S?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Genmab A/S has a net margin of 19.08% compared to Mirum Pharmaceuticals' net margin of -139.18%. Genmab A/S's return on equity of 14.89% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Genmab A/S	19.08%	14.89%	7.73%

Mirum Pharmaceuticals currently has a consensus target price of $137.31, suggesting a potential upside of 40.89%. Genmab A/S has a consensus target price of $39.50, suggesting a potential upside of 18.87%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Mirum Pharmaceuticals is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Genmab A/S has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$618.07M	10.24	-$23.36M	-$14.55	N/A
Genmab A/S	$4.13B	5.02	$963M	$1.27	26.17

In the previous week, Mirum Pharmaceuticals had 15 more articles in the media than Genmab A/S. MarketBeat recorded 20 mentions for Mirum Pharmaceuticals and 5 mentions for Genmab A/S. Mirum Pharmaceuticals' average media sentiment score of 1.27 beat Genmab A/S's score of 0.98 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

7.1% of Genmab A/S shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Genmab A/S beats Mirum Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Mirum Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRM vs. The Competition

Export

Metric	Mirum Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.33B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-6.70	11.62	273.16	25.45
Price / Sales	10.24	1,295.89	605.01	76.63
Price / Cash	1,911.77	106.39	76.74	53.00
Price / Book	-609.13	16.53	12.98	6.14
Net Income	-$23.36M	-$22.80M	$3.48B	$348.86M
7 Day Performance	1.19%	-0.31%	0.13%	-0.80%
1 Month Performance	-13.44%	9.80%	7.08%	4.13%
1 Year Performance	31.93%	55.66%	24.67%	15.17%

Mirum Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRM Mirum Pharmaceuticals	3.7178 of 5 stars	$97.46 -2.3%	$137.31 +40.9%	+31.9%	$6.33B	$618.07M	N/A	140	News Coverage Analyst Forecast
MRNA Moderna	1.4862 of 5 stars	$174.38 +177.0%	$56.56 -67.6%	+472.8%	$25.14B	$1.94B	N/A	4,700	Trending News Analyst Upgrade Gap Down High Trading Volume
INCY Incyte	3.6928 of 5 stars	$128.47 +4.0%	$121.65 -5.3%	+47.0%	$25.03B	$5.14B	16.37	2,844	News Coverage Positive News Analyst Upgrade
BNTX BioNTech	3.2882 of 5 stars	$113.12 +22.0%	$127.81 +13.0%	+2.1%	$23.46B	$3.25B	N/A	7,807	Trending News Options Volume Gap Down High Trading Volume
UTHR United Therapeutics	4.7561 of 5 stars	$529.14 +2.1%	$646.00 +22.1%	+69.1%	$22.23B	$3.18B	18.93	1,400	News Coverage Positive News Analyst Downgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRM) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. MRNA, INCY, BNTX, UTHR, and GMAB

How does Mirum Pharmaceuticals compare to Moderna?

Summary

How does Mirum Pharmaceuticals compare to Incyte?

Summary

How does Mirum Pharmaceuticals compare to BioNTech?

Summary

How does Mirum Pharmaceuticals compare to United Therapeutics?

Summary

How does Mirum Pharmaceuticals compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mirum Pharmaceuticals (MIRM) Competitors

MIRM vs. MRNA, INCY, BNTX, UTHR, and GMAB

How does Mirum Pharmaceuticals compare to Moderna?

Which has higher valuation and earnings, MIRM or MRNA?

Is MIRM or MRNA more profitable?

Do analysts recommend MIRM or MRNA?

Do institutionals & insiders have more ownership in MIRM or MRNA?

Which has more volatility and risk, MIRM or MRNA?

Does the media favor MIRM or MRNA?

Summary

How does Mirum Pharmaceuticals compare to Incyte?

Is MIRM or INCY more profitable?

Do analysts prefer MIRM or INCY?

Which has stronger earnings & valuation, MIRM or INCY?

Do institutionals and insiders have more ownership in MIRM or INCY?

Which has more risk & volatility, MIRM or INCY?

Does the media favor MIRM or INCY?

Summary

How does Mirum Pharmaceuticals compare to BioNTech?

Is BNTX or MIRM more profitable?

Do institutionals & insiders have more ownership in BNTX or MIRM?

Which has more risk & volatility, BNTX or MIRM?

Which has stronger valuation and earnings, BNTX or MIRM?

Does the media prefer BNTX or MIRM?

Do analysts rate BNTX or MIRM?

Summary

How does Mirum Pharmaceuticals compare to United Therapeutics?

Do analysts recommend MIRM or UTHR?

Does the media favor MIRM or UTHR?

Which has more risk and volatility, MIRM or UTHR?

Do insiders and institutionals believe in MIRM or UTHR?

Which has better earnings and valuation, MIRM or UTHR?

Is MIRM or UTHR more profitable?

Summary

How does Mirum Pharmaceuticals compare to Genmab A/S?

Is MIRM or GMAB more profitable?

Do analysts recommend MIRM or GMAB?

Which has preferable earnings and valuation, MIRM or GMAB?

Does the media refer more to MIRM or GMAB?

Which has more risk & volatility, MIRM or GMAB?

Do insiders & institutionals have more ownership in MIRM or GMAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM vs. The Competition

Mirum Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools